In contrast, WNT5A has been shown to positively drive EMT-like changes in gastric cancer, pancreatic cancer, ovarian cancer and malignant melanomas, where WNT5A acts as a tumor promoter [22–26]. Here, WNT5A is linked to ovarian carcinoma.